Loading...
Pilot trial of CRLX101 in patients with advanced, chemotherapy-refractory gastroesophageal cancer
BACKGROUND: CRLX101 is an investigational nanoparticle-drug conjugate with a camptothecin payload. Preclinical evidence indicated preferential uptake in tumors, and tumor xenograft models demonstrate superiority of CRLX101 over irinotecan. A pilot trial was conducted at recommended phase 2 dosing (R...
Na minha lista:
| Udgivet i: | J Gastrointest Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
AME Publishing Company
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5750185/ https://ncbi.nlm.nih.gov/pubmed/29299355 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2017.08.10 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|